FITC Annexin V

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5
Ave. Rating
Submit a Review
Product Citations
publications
AnnexinV_FITC_092908.jpg
Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • AnnexinV_FITC_092908.jpg
    Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • B_AnnexinV_FITC_092908.jpg
See FITC spectral data
Cat # Size Price Save
640905 25 tests ¥16,170
640906 100 tests ¥38,220
640945 300 tests ¥79,800
Description

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (cat. no. 422201) is recommended for use with Annexin V staining.Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat. No. 425305), Helix NP™ Green (Cat.  No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details
Technical data sheet

Product Details

Verified Reactivity
All mammalian species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The purified protein was conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Annexin V Staining
1. Wash cells twice with cold BioLegend cell staining buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x106 cells/mL.
2. Transfer 100 µL of cell suspension in 5 ml test tube.
3. Add 5 µL of FITC Annexin V.
4. Add 10 µL of PI solution (Cat. No. 421301) or 7-AAD (Cat. No. 420403/420404).
5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
6. Add 400 µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. Analyze by flow cytometry.


For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Koopman G, et al. 1994. Blood 84:1415.
  2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
  3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
  4. Sekine C, et al. 2009. Int Immunol. PubMed
  5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
  6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
  7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  8. Speth C,et al. 2013. J Infect Dis. 207:823. PubMed
  9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
  11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
  12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed
  13. Sequier S, et al. 2013. PLoS One. 8:70937. PubMed
  14. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  15. Chen YL, et al. 2013. J Exp Med. PubMed
  16. Lin WH, et al. 2014. PLoS One. 9:83160. PubMed
  17. Salge-Bartles U, 2014. Thromb res. 133:244. PubMed
  18. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  19. Intermann J, et al. 2014. Cell Signal. 26:1567. PubMed
  20. de Vires M, 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  21. M Parrula MC, et al. 2014. Virus Res. 189:206. PubMed
  22. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  23. Tsou WI, et al. 2014. J Biol Chem. 289:25750. PubMed
  24. Awojoodu AO, et al. 2014. Blood. 124:1941. PubMed
  25. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  26. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
Product Citations
  1. Derudder E, et al. 2016. Proc Natl Acad Sci U S A. 113: 5065-5070. PubMed
  2. Yao Z, et al. 2018. J Virol. 92:00:00. PubMed
  3. Uriostegui–Arcos M, et al. 2020. Open Biol. 10:200050. PubMed
  4. Zhang T, et al. 2022. EBioMedicine. 77:103872. PubMed
  5. Dhoonmoon A, et al. 2022. Nat Commun. 13:5063. PubMed
  6. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  7. Kim EH, et al. 2020. Elife. 9:00. PubMed
  8. Kitayama J, et al. 2016. PLoS One. 11: 0154542. PubMed
  9. Gedye C, et al. 2016. Sci Rep. 6: 25220. PubMed
  10. Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed
  11. Bouhaddou M, et al. 2018. PLoS Comput Biol. 14:e1005985. PubMed
  12. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  13. Dowling CM, et al. 2021. Sci Adv. 7:. PubMed
  14. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  15. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  16. Fujii T, et al. 2015. Proc Natl Acad Sci U S A. 112: 12800 - 12805. PubMed
  17. Cardoso B, et al. 2015. PLoS One. 10: 0143897. PubMed
  18. Alcon C, et al. 2020. Cell Death Dis. 0.898611111. PubMed
  19. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  20. Feng W, et al. 2017. Nat Commun. 0.697916667. PubMed
  21. Jones PD, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1711. PubMed
  22. Figueiredo T, et al. 2020. Mol Psychiatry. . PubMed
  23. Lopes-Coelho F, et al. 2021. Front Oncol. 11:656229. PubMed
  24. Wang Q, et al. 2022. Nat Commun. 13:3022. PubMed
  25. Olelewe C, et al. 2022. iScience. 25:104340. PubMed
  26. Ramalingam P, et al. 2020. J Exp Med. 217:00:00. PubMed
  27. Bowen ME, et al. 2019. Dev Cell. 50:212. PubMed
  28. Sales–Dias J, et al. 2019. PLoS One. 14:e0217002. PubMed
  29. Santos LC, et al. 2019. Nat Commun. 1.328472222. PubMed
  30. Lim JA, et al. 2018. BMC Cancer. 0.860416667. PubMed
  31. Venter C, et al. 2017. Cell Physiol Biochem. 43:1288. PubMed
  32. Kim Y, et al. 2020. J Neurochem. 155:177. PubMed
  33. Hassan MIA, et al. 2021. Comput Struct Biotechnol J. 19:880. PubMed
  34. Soprano M, et al. 2016. PLoS One. 11: 0155970. PubMed
  35. Macpherson L, et al. 2020. Nature. 577:266. PubMed
  36. Karavasili C, et al. 2017. International Journal of Pharmaceutics. 10.1016/j.ijpharm.2017.05.061. PubMed
  37. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  38. Noguchi F, et al. 2017. Mol Cancer Ther. 1.316666667. PubMed
  39. Kumar S, et al. 2018. Cancers (Basel). 0.724305556. PubMed
  40. Fortin J, et al. 2020. Cancer Cell. 37:308. PubMed
  41. Vereertbrugghen A, et al. 2021. Front Oncol. 11:598319. PubMed
  42. Sun V, et al. 2021. Front Immunol. 12:716661. PubMed
  43. Coray M, et al. 2022. Int J Mol Sci. 23:. PubMed
  44. He C, et al. 2021. Oncoimmunology. 1897295:10. PubMed
  45. Pfalzgraff A, et al. 2016. Sci Rep. 6:31577. PubMed
  46. O'Neill K, et al. 2016. Genes Dev. 30: 973-988. PubMed
  47. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
  48. Vries M, et al. 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  49. Chen MS, et al. 2019. Mol Cancer Res. 17:697. PubMed
  50. Ni F, et al. 2019. Cell Stem Cell. 24:608. PubMed
  51. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  52. Greenblatt SM, et al. 2018. Cancer Cell. 33:1111. PubMed
  53. Naqvi N,et al. 2017. Sci Rep.. 10.1038/s41598-017-12753-1. PubMed
  54. Wang M, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.097. PubMed
  55. Beeravolu N, McKee C, Chaudhry G 2017. J App Toxicol. 10.1002/jat.3469. PubMed
  56. Kim OV, et al. 2022. iScience. 25:104654. PubMed
  57. Shahzadi SK, et al. 2022. Clin Sci (Lond). 136:181. PubMed
  58. Kolbrink B, et al. 2022. Biochem J. 479:259. PubMed
  59. Parrula M, et al. 2014. Virus Res. 189:206. PubMed
  60. Brigger D, et al. 2015. Cell Death Dis. 6: e1861. PubMed
  61. Zhang J, et al. 2016. Cell Death Dis. 7:e2266. PubMed
  62. Wang D, et al. 2016. J Cell Sci. 129: 2261 - 2272. PubMed
  63. Uchtenhagen H, et al. 2016. Nat Commun. 7:12614. PubMed
  64. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  65. Esteghamat F, et al. 2019. Nat Genet. 51:1233. PubMed
  66. Blümel E, et al. 2020. Oncoimmunology. 9:1751561. PubMed
  67. Sekine C, et al. 2009. Int Immunol. 1.079861111. PubMed
  68. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  69. O'Connor MJ, et al. 2021. Oncogene. 40:4872. PubMed
  70. Madala HR, et al. 2020. Cancer Res. 3492:80. PubMed
  71. Clements KE, et al. 2020. Nat Commun. 4.706944444. PubMed
  72. Rauzan M, et al. 2017. PLoS One. 12:e0174107. PubMed
  73. Liu Y, et al. 2017. Acta Biomater. 10.1016/j.actbio.2017.08.021. PubMed
  74. Chiani M, et al. 2017. Artif Cells Nanomed Biotechnol. 10.1080/21691401.2017.1337029. PubMed
  75. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  76. Martín Monreal MT, et al. 2021. Front Immunol. 12:716250. PubMed
  77. Schmitz RL, et al. 2021. Cells. 10:. PubMed
  78. Babaei A, et al. 2021. Adv Pharm Bull. 11:361. PubMed
  79. Salge-Bartels U, et al. 2014. Thromb Res. 133:244. PubMed
  80. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  81. Ligtenberg M, et al. 2016. J Immunol. 196: 759 - 766. PubMed
  82. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  83. Herold N, et al. 2017. Nat Med. 23:256-263. PubMed
  84. Xie S, et al. 2021. Sci Rep. 0.660416667. PubMed
  85. Müller I, et al. 2020. Mol Cell. 970:77. PubMed
  86. Kamiyama N, et al. 2017. Antiviral Res. 10.1016/j.antiviral.2017.08.007. PubMed
  87. Montero–Herradón S, et al. 2017. Organogenesis. 0.675. PubMed
  88. Nunes SC, et al. 2018. Sci Rep. 6.939583333. PubMed
  89. Sharif T, et al. 2018. Autophagy. 1.101388889. PubMed
  90. Eichelmann AK, et al. 2018. Sci Rep. 8:17553. PubMed
  91. Blümel E, et al. 2019. Oncoimmunology. 8:e1641387. PubMed
  92. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  93. Norkin M, et al. 2021. Cell Rep. 35:109026. PubMed
  94. Krauss PL, et al. 2021. Front Immunol. 12:730672. PubMed
  95. Zhu Y, et al. 2022. Clin Transl Med. 12:e887. PubMed
  96. Khatib JB, et al. 2022. Oncotarget. 13:1078. PubMed
  97. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  98. Chheda Z, et al. 2016. J Immunol. 197: 2016 - 2026. PubMed
  99. Slone E, et al. 2015. J Leukoc Biol. 98: 791 - 804. PubMed
  100. Séguier S, et al. 2013. PLoS One. 8:70937. PubMed
  101. Liu H, et al. 2020. Cell Death Dis. 0.767361111. PubMed
  102. Zervou S, et al. 2017. PLoS One.. 10.1371/journal.pone.0182994. PubMed
  103. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  104. Matsuda K, et al. 2021. Cell Rep Methods. 1:100122. PubMed
  105. Vanoli F, et al. 2021. Oncogene. 40:5095. PubMed
  106. Liu H, et al. 2021. J Immunother Cancer. 9:. PubMed
  107. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  108. Li Y, et al. 2021. Sci Transl Med. 13:. PubMed
  109. Meyer N, et al. 2021. J Clin Med. 10:. PubMed
  110. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  111. Douguet L, et al. 2016. PLoS One. 11:e0166164. PubMed
  112. Toutounchian J, et al. 2016. Mol Pharmacol. 91(1):1-13. PubMed
  113. Pajarillo E, et al. 2020. J Biol Chem. 295:3040. PubMed
  114. Litzenburger UM, et al. 2017. Genome Biol. 18:15. PubMed
  115. Rajavel T, et al. 2017. Sci Rep. 2.665277778. PubMed
  116. Grujic M, et al. 2010. J Immunol. 185:1730. PubMed
  117. Gholamrezaei M, et al. 2021. Iran J Parasitol. 15:475. PubMed
  118. Meyer N, et al. 2021. Int J Mol Sci. 22:. PubMed
  119. Kolbrink B, et al. 2022. Cell Mol Life Sci. 79:387. PubMed
  120. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  121. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. PubMed
  122. Becker A, et al. 2016. Sci Rep. 6: 33847. PubMed
  123. Kumai T, et al. 2015. Sci Rep. 5:16280. PubMed
  124. Polak R, et al. 2015. Blood. 126: 2404 - 2414. PubMed
  125. Matsumoto A, et al. 2019. J Extracell Vesicles. 9:1696517. PubMed
  126. Pirali T, et al. 2017. ChemMedChem. 1.570833333. PubMed
  127. Ishida M, et al. 2021. Int J Mol Sci. 22:. PubMed
  128. Lee DH, et al. 2020. Circ Res. 127:1182. PubMed
  129. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  130. Tsou W, et al. 2014. J Biol Chem. 289:25750. PubMed
  131. Dhoonmoon A, et al. 2020. Nucleic Acids Res. 48:7252. PubMed
  132. Hafez A, et al. 2017. Oncogenesis. 10.1038/oncsis.2017.46. PubMed
  133. Putheti P, et al. 2010. PLoS One. 5:e8706. PubMed
  134. Nastasi C, et al. 2021. Sci Rep. 11:1458. PubMed
  135. Molinar-Inglis O, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  136. Erdogan M, et al. 2022. Chem Biodivers. 19:e202200659. PubMed
  137. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  138. Liu B, et al. 2016. J Biol Chem. 291: 23869 - 23881. PubMed
  139. Lhuillier C, et al. 2015. J Biol Chem. 290: 16797 - 16811. PubMed
  140. Passaro C, et al. 2013. Endocr Relat Cancer. 20:633. PubMed
  141. Mulik R, et al. 2010. Int J Pharm. 398:190. PubMed
  142. Speth C, et al. 2013. J Infect Dis. 207:823. PubMed
  143. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  144. Lee HW, et al. 2018. Am J Physiol Renal Physiol. 314:F280. PubMed
  145. Ki H, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.09.118. PubMed
  146. Shadboorestan A, et al. 2022. Iran J Basic Med Sci. 25:506. PubMed
  147. Huang Y, et al. 2022. Front Cell Dev Biol. 9:837777. PubMed
  148. Babaei A, et al. 2020. Daru. 28:555. PubMed
  149. King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed
  150. Lin W, et al. 2014. PLoS One. 9:83160. PubMed
  151. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  152. CO L, et al. 2015. Nat Commun. 6: 7739. PubMed
  153. Huang YL, et al. 2020. Elife. 9:00. PubMed
  154. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  155. Di Somma S, et al. 2019. Cancers (Basel). 1.70625. PubMed
  156. Abu El Maaty MA, et al. 2021. Sci Adv. 7: . PubMed
  157. Bahl S, et al. 2021. Cell Death Dis. 12:469. PubMed
  158. Jackson LM, et al. 2021. Nucleic Acids Res. 49:12855. PubMed
  159. Faria M, et al. 2017. PLoS One. 12(2):e0172689. PubMed
  160. Jones P, et al. 2016. J Biol Chem. 291: 16318 - 16327. PubMed
  161. Awojoodu A, et al. 2014. Blood. 124:1941. PubMed
  162. Intemann J, et al. 2014. Cell Signal. 26:1567. PubMed
  163. Labi V, et al. 2019. Genes Dev. 33:1673. PubMed
  164. Fang P, et al. 2019. Commun Biol. 0.315972222. PubMed
  165. Kumar S, et al. 2019. Int J Cancer. 146:1652. PubMed
  166. Zhao CC, et al. 2018. Oncol Rep. 40:3392. PubMed
  167. Schleicher EM, et al. 2018. Nucleic Acids Res. 46:8908. PubMed
  168. Thomas A, et al. 2017. PLoS One.. 10.1371/journal.pone.0183542. PubMed
  169. Tatangelo V, et al. 2022. Front Oncol. 12:877495. PubMed
  170. Alcon C, et al. 2021. Cells. 10:. PubMed
  171. Cao H, et al. 2021. Nat Commun. 12:1792. PubMed
  172. Clements KE, et al. 2018. Nucleic Acids Res. 46:8898. PubMed
  173. Bostanabad SY, et al. 2021. Sci Rep. 11:1539. PubMed
  174. Monzen S, et al. 2022. Mol Clin Oncol. 16:19. PubMed
  175. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
  176. Wu J, et al. 2021. Adv Sci (Weinh). 8:e2101029. PubMed
  177. Zhang Y, et al. 2021. Cell Death Dis. 0.563194444. PubMed
  178. Kang JH, et al. 2020. Cell Death Dis. 0.803472222. PubMed
  179. Dewdney B, et al. 2020. Sci Rep. 10:16769. PubMed
  180. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  181. Coutaz M, et al. 2016. Sci Rep. 6:39117. PubMed
  182. Akane K, et al. 2016. Proc Natl Acad Sci U S A. 113: 2460 - 2465. PubMed
  183. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  184. Chen Y, et al. 2013. J Exp Med. 210:2515. PubMed
  185. Mendès C, et al. 2019. Sci Rep. 9:14107. PubMed
  186. Lopes–Coelho F, et al. 2017. Oncotarget. 8:82803. PubMed
  187. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  188. Thanuthanakhun N, et al. 2017. PLoS One. . 10.1371/journal.pone.0187610. PubMed
  189. Kuntz E, et al. 2017. Nat Med. 10.1038/nm.4399. PubMed
  190. Tu Z, et al. 2022. Cell Rep. 40:111072. PubMed
  191. Bensberg M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  192. Paparella AS, et al. 2021. Nat Commun. 12:6285. PubMed
  193. Huang YL, et al. 2021. iScience. 24:103168. PubMed
  194. Bottardi S, et al. 2020. Exp Hematol. 68:88. PubMed
  195. Siddhartha V, et al. 2017. Artif Cells Nanomed Biotechnol . 10.1080/21691401.2017.1313267. PubMed
  196. He J, et al. 2017. FASEB J. 31:2893. PubMed
  197. Lyu X, et al. 2019. BMC Genomics. 1.235416667. PubMed
  198. Jing Y, et al. 2019. J Allergy Clin Immunol. 144:1377. PubMed
  199. Quan M, et al. 2019. Oncol Rep. 41:3051. PubMed
  200. Kasikara C, et al. 2021. J Clin Invest. 131:. PubMed
  201. Ning N, et al. 2022. Theranostics. 12:5537. PubMed
  202. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  203. Pahari S, et al. 2020. Autophagy. 1.375694444. PubMed
  204. Schleicher EM, et al. 2020. PLoS Genet. 16:e1009176. PubMed
  205. Langsch S, et al. 2016. Cancer Res . 76: 4160 - 4169. PubMed
  206. Xiong R, et al. 2015. Mol Pharmacol. 88: 1045 - 1054. PubMed
  207. Hellmann J, et al. 2013. J Immunol. 191:1383. PubMed
  208. Juel H, et al. 2013. PLoS One. 8:64619. PubMed
  209. Gill K, et al. 2013. Biochim Biophys Acta. 1830:2763. PubMed
  210. Young MM, et al. 2019. Cell Death Dis. 1.004861111. PubMed
  211. Santos I, et al. 2019. Nutrients. 2.210416667. PubMed
  212. Vancsik T, et al. 2019. Cancer Med. 3.313888889. PubMed
  213. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  214. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  215. Wang Y, et al. 2022. Front Cardiovasc Med. 9:876087. PubMed
  216. Shankman LS, et al. 2021. Curr Biol. 31:2469. PubMed
RRID
AB_2561291 (BioLegend Cat. No. 640905)
AB_2561292 (BioLegend Cat. No. 640906)
AB_2629519 (BioLegend Cat. No. 640945)

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID
UniProt
View information about Annexin V on UniProt.org

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 5    Revision Date: 04/20/2020

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account